Want to see DE:FME full AI Analyst Report?
Top Page
Fresenius Medical Care AG & Co. KGaA
(XETRA:FME)
Select Model
Select Model
Rating:64Neutral
Price Target:
€44.00
▲(1.69% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by improving financial performance (strong TTM revenue inflection and better operating margins) and a supportive valuation (moderate P/E with a ~3.35% dividend yield). These positives are tempered by mixed technicals (RSI below 50 and price below the 20-day average), along with only mid-level net margins and slightly softer recent free-cash-flow momentum.
Positive Factors
Revenue and EBIT Improvement
The sharp top-line acceleration and wider operating margin indicate improved business execution and operating leverage. If sustained, this combination can strengthen earnings capacity across FME’s care delivery and dialysis products businesses.
Negative Factors
Mid-Level Net Margins
Despite stronger EBIT performance, limited net profitability leaves less earnings protection against reimbursement pressure, labor costs, manufacturing expenses, and other operating volatility. Margin improvement may therefore not fully translate into durable bottom-line growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and EBIT Improvement
The sharp top-line acceleration and wider operating margin indicate improved business execution and operating leverage. If sustained, this combination can strengthen earnings capacity across FME’s care delivery and dialysis products businesses.
Read all positive factors
Fresenius Medical Care AG & Co. KGaA (FME) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€10.87B
Dividend Yield3.71%
Average Volume (3M)529.60K
Price to Earnings (P/E)12.1
Beta (1Y)0.44
Revenue Growth-0.47%
EPS Growth48.60%
CountryDE
Employees108,165
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)3.32
Shares Outstanding268,564,640
10 Day Avg. Volume492,004
30 Day Avg. Volume529,597
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.66Price Target Upside-12.98% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)4.07
Revenue Forecast (FY)€19.45B
Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model
Company Description
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essent...
How the Company Makes Money
FME generates revenue primarily from two complementary activities: (1) delivering dialysis and related clinical services and (2) selling dialysis-related products and services. On the care delivery side, it earns fees for providing in-center dialy...
Fresenius Medical Care AG & Co. KGaA Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
63
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.43B | 19.63B | 19.34B | 19.45B | 19.40B | 17.62B |
| Gross Profit | 5.12B | 5.03B | 4.76B | 4.93B | 5.31B | 5.08B |
| EBITDA | 3.53B | 3.34B | 3.21B | 2.93B | 3.22B | 3.42B |
| Net Income | 937.80M | 978.00M | 537.91M | 499.00M | 673.40M | 969.31M |
Balance Sheet | ||||||
| Total Assets | 31.29B | 31.00B | 33.57B | 33.93B | 35.75B | 34.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 1.73B | 1.45B | 1.54B | 1.44B | 1.62B |
| Total Debt | 10.96B | 10.80B | 10.98B | 12.05B | 13.21B | 13.32B |
| Total Liabilities | 17.76B | 16.72B | 17.80B | 19.10B | 20.30B | 20.39B |
| Stockholders Equity | 12.56B | 13.31B | 14.58B | 13.62B | 15.45B | 13.98B |
Cash Flow | ||||||
| Free Cash Flow | 1.78B | 1.77B | 1.69B | 1.94B | 1.44B | 1.64B |
| Operating Cash Flow | 2.83B | 2.68B | 2.39B | 2.63B | 2.17B | 2.49B |
| Investing Cash Flow | -896.02M | -693.55M | -84.94M | -544.23M | -734.73M | -1.20B |
| Financing Cash Flow | -2.57B | -1.43B | -2.57B | -1.86B | -1.62B | -1.02B |
Fresenius Medical Care AG & Co. KGaA Technical Analysis
Neutral
43.27
Price Trends
41.80
Negative
39.46
Positive
38.80
Positive
Market Momentum
-0.32
Positive
42.25
Neutral
14.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Neutral. The current price of 43.27 is above the 20-day moving average (MA) of 42.24, above the 50-day MA of 41.80, and above the 200-day MA of 38.80, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 42.25 is Neutral, neither overbought nor oversold. The STOCH value of 14.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:FME.
Fresenius Medical Care AG & Co. KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.78B | 12.12 | 10.62% | 2.35% | 6.37% | 71.55% | |
66 Neutral | €25.77B | 16.95 | 7.89% | 2.40% | 5.30% | 35.29% | |
65 Neutral | €237.50M | 8.31 | 11.54% | 0.94% | 2.94% | -14.28% | |
64 Neutral | €10.87B | 12.09 | 7.21% | 3.44% | -0.47% | 48.60% | |
60 Neutral | €1.42B | 43.42 | 4.19% | 1.82% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €984.00M | 22.97 | 3.04% | 1.55% | 4.91% | 11.71% |
* General Sector Average
DE:FME
Fresenius Medical Care AG & Co. KGaA
40.14
-1.78
-4.26%
DE:COP
CompuGroup Medical
27.40
4.47
19.50%
DE:DRW3
Draegerwerk AG & Co. KGaA
110.80
43.45
64.51%
DE:FRE
Fresenius SE & Co. KGaA
46.60
0.20
0.44%
DE:MED
MEDICLIN
5.05
2.02
66.83%
DE:RHK
RHON-KLINIKUM AG
14.70
3.09
26.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.